Troglitazone is a PPAR-γ agonist that was used to enhance insulin sensitivity in patients with type 2 diabetes but was withdrawn from the market in 2000 by the FDA due to numerous cases of liver failure from DILI. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.